Metagenomi Therapeutics Inc. (MGX)
MGX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/0001193125-26-093976-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MGX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001785279 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $25.2M |
| Net income | -$87.9M |
| Operating income | -$96.0M |
| Net margin | -348.5% |
| Operating margin | -380.9% |
| Revenue growth | -51.8% |
| Cash | $41.7M |
| Total assets | $221.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $36.1M cash; operating cash flow -$20.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 37,805,669 (2026-11-06). | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, San Jose, California, United States | PCAOB Form AP 2026-03-19 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $23K, sold $33K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $2.2M | -$21.1M | -$19.1M | $36.1M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$27.5M | -$19.5M | $39.0M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2026 2026-03-31 | $1.2M | -$23.1M | -$21.2M | $25.3M | No debt tags | $22.3M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $3.9M | -$22.5M | -$23.5M | $41.7M | No debt tags | $25.2M | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $8.7M | -$20.4M | -$21.3M | $32.8M | No debt tags | $30.9M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $8.5M | -$19.9M | -$21.3M | $26.9M | No debt tags | $33.8M | 10-Q 2025-08-12 |
| Q1 2025 2025-03-31 | $4.1M | -$25.0M | -$22.8M | $29.2M | No debt tags | $45.3M | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $9.6M | -$23.4M | -$26.3M | $27.4M | No debt tags | $52.3M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-03-17 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 157 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.4% |
| 1 month | -24.5% |
| 3 months | -43.7% |
| Year to date | -57.3% |
| 1 year | -59.3% |
| From 52-week high | -62.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| EVAX | Evaxion A/S American Depositary Share | $2.77 | +0.54% | $25.5M |
| PTHS | Pelthos Therapeutics Inc. | $7.15 | -3.90% | $28.1M |
| SAEN | Genenta Science S.p.A. | $0.6000 | -7.66% | $28.9M |
| CVM | Cel-Sci Corporation | $1.66 | +29.69% | $29.2M |
| INMB | INmune Bio Inc. | $0.9464 | -9.87% | $29.3M |
| LONA | LeonaBio Inc. | $3.23 | -6.92% | $30.4M |
| KLRS | Kalaris Therapeutics Inc. | $1.46 | -7.30% | $34.8M |
| BSEM | BioStem Technologies Inc. | $0.9601 | -8.56% | $18.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier